-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AD-214
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AD-214 Drug Details AD-214 is under development for the treatment of gastroesophageal reflux disease...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AD-214
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AD-214 Drug Details AD-214 is under development for the treatment of interstitial lung disease,...
-
Product Insights
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Idiopathic Pulmonary Fibrosis (IPF) symptoms include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness, and weight loss. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents, and anticoagulants. The IPF pipeline drugs market research report provides an analysis of the IPF drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history...
-
Product Insights
Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis – Drugs In Development, 2022, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Kidney Disease (Chronic Renal Failure) is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue, weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease pipeline drugs market research report provides comprehensive information on the Chronic Renal Failure targeted therapeutics, complete with analysis by indications, stage of...
-
Product Insights
Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome. The NASH drugs in development market research report provides comprehensive information on the...
-
Sector Analysis
Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Product Insights
Liver Diseases Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Liver Diseases Global Clinical Trials Review, H2, 2017" provides an overview of Liver Diseases clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Diseases. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Australia Diagnostic Imaging Market Outlook to 2025 – Angio Suites, Bone Densitometers, C-Arms, Computed Tomography (CT) Systems and Others
GlobalData’s “Australia Diagnostic Imaging Market Outlook to 2025” is a comprehensive databook report, covering key market data on the Australia Diagnostic Imaging market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Angio Suites, Bone Densitometers, C-Arms, Computed Tomography (CT) Systems, Contrast Media Injectors, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems, X-ray Systems. The Australia Diagnostic Imaging Market report provides key information and data on: • Annualized market revenues (USD), volume...